Antimalarial drugs - host targets (re)visited
Every year, forty percent of the world population is at risk of contracting malaria. Hopes for the erradication of this disease during the 20th century were dashed by the ability of Plasmodium falciparum, its most deadly causative agent, to develop resistance to available drugs. Efforts to produce a...
Gespeichert in:
| Veröffentlicht in: | Biotechnology journal 2006-03, Vol.1 (3), p.321-332 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 332 |
|---|---|
| container_issue | 3 |
| container_start_page | 321 |
| container_title | Biotechnology journal |
| container_volume | 1 |
| creator | Cunha-Rodrigues, Margarida Prudêncio, Miguel Mota, Maria M. Haas, Werner |
| description | Every year, forty percent of the world population is at risk of contracting malaria. Hopes for the erradication of this disease during the 20th century were dashed by the ability of Plasmodium falciparum, its most deadly causative agent, to develop resistance to available drugs. Efforts to produce an effective vaccine have so far been unsuccessful, enhancing the need to develop novel antimalarial drugs. In this review, we summarize our knowledge concerning existing antimalarials, mechanisms of drug‐resistance development, the use of drug combination strategies and the quest for novel anti‐plasmodial compounds. We emphasize the potential role of host genes and molecules as novel targets for newly developed drugs. Recent results from our laboratory have shown Hepatocyte Growth Factor/MET signaling to be essential for the establishment of infection in hepatocytes. We discuss the potential use of this pathway in the prophylaxis of malaria infection. |
| doi_str_mv | 10.1002/biot.200500038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68719468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20246855</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4678-54418ed63ac13f03ce4132adfec3f8a7976677df3526b6421db35d23ec082dcf3</originalsourceid><addsrcrecordid>eNqFkM1PwjAYhxujEUSvHs1ORg_Dfq3tjkDkIyFywZh4abq1w-lg2HYq_70jW9Abp76H5_ckfQC4RrCPIMQPSV76PoYwghAScQK6SDAYcoLoaXszzkQHXDj3DiGNCKTnoIOYiDlHuAvCwcbna1Uom6si0LZauSAM3krnA6_syngX3Flz_5W73Bt9Cc4yVThz1b498Dx-XI6m4XwxmY0G8zCljIswohQJoxlRKSIZJKmhiGClM5OSTCgec8Y41xmJMEsYxUgnJNKYmBQKrNOM9MBt493a8rMyzst17lJTFGpjyspJJjiKKRNHQQxxjUVRDfYbMLWlc9Zkcmvrf9udRFDuS8p9SXkoWQ9uWnOVrI3-w9t0NRA3wHdemN0RnRzOFsv_8rDZ5s6bn8NW2Q_JOOGRfHmaSD6evw4RRnJKfgGuhI0k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20246855</pqid></control><display><type>article</type><title>Antimalarial drugs - host targets (re)visited</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><creator>Cunha-Rodrigues, Margarida ; Prudêncio, Miguel ; Mota, Maria M. ; Haas, Werner</creator><creatorcontrib>Cunha-Rodrigues, Margarida ; Prudêncio, Miguel ; Mota, Maria M. ; Haas, Werner</creatorcontrib><description>Every year, forty percent of the world population is at risk of contracting malaria. Hopes for the erradication of this disease during the 20th century were dashed by the ability of Plasmodium falciparum, its most deadly causative agent, to develop resistance to available drugs. Efforts to produce an effective vaccine have so far been unsuccessful, enhancing the need to develop novel antimalarial drugs. In this review, we summarize our knowledge concerning existing antimalarials, mechanisms of drug‐resistance development, the use of drug combination strategies and the quest for novel anti‐plasmodial compounds. We emphasize the potential role of host genes and molecules as novel targets for newly developed drugs. Recent results from our laboratory have shown Hepatocyte Growth Factor/MET signaling to be essential for the establishment of infection in hepatocytes. We discuss the potential use of this pathway in the prophylaxis of malaria infection.</description><identifier>ISSN: 1860-6768</identifier><identifier>EISSN: 1860-7314</identifier><identifier>DOI: 10.1002/biot.200500038</identifier><identifier>PMID: 16897712</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Animals ; Antimalarials - therapeutic use ; Drug Delivery Systems - methods ; Drug Delivery Systems - trends ; Drug Design ; Drug Resistance ; HGF/MET ; Humans ; Malaria ; Malaria - drug therapy ; Malaria - physiopathology ; Plasmodium falciparum ; Prophylaxis ; Treatment Outcome</subject><ispartof>Biotechnology journal, 2006-03, Vol.1 (3), p.321-332</ispartof><rights>Copyright © 2006 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4678-54418ed63ac13f03ce4132adfec3f8a7976677df3526b6421db35d23ec082dcf3</citedby><cites>FETCH-LOGICAL-c4678-54418ed63ac13f03ce4132adfec3f8a7976677df3526b6421db35d23ec082dcf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fbiot.200500038$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16897712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cunha-Rodrigues, Margarida</creatorcontrib><creatorcontrib>Prudêncio, Miguel</creatorcontrib><creatorcontrib>Mota, Maria M.</creatorcontrib><creatorcontrib>Haas, Werner</creatorcontrib><title>Antimalarial drugs - host targets (re)visited</title><title>Biotechnology journal</title><addtitle>Biotechnology Journal</addtitle><description>Every year, forty percent of the world population is at risk of contracting malaria. Hopes for the erradication of this disease during the 20th century were dashed by the ability of Plasmodium falciparum, its most deadly causative agent, to develop resistance to available drugs. Efforts to produce an effective vaccine have so far been unsuccessful, enhancing the need to develop novel antimalarial drugs. In this review, we summarize our knowledge concerning existing antimalarials, mechanisms of drug‐resistance development, the use of drug combination strategies and the quest for novel anti‐plasmodial compounds. We emphasize the potential role of host genes and molecules as novel targets for newly developed drugs. Recent results from our laboratory have shown Hepatocyte Growth Factor/MET signaling to be essential for the establishment of infection in hepatocytes. We discuss the potential use of this pathway in the prophylaxis of malaria infection.</description><subject>Animals</subject><subject>Antimalarials - therapeutic use</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Delivery Systems - trends</subject><subject>Drug Design</subject><subject>Drug Resistance</subject><subject>HGF/MET</subject><subject>Humans</subject><subject>Malaria</subject><subject>Malaria - drug therapy</subject><subject>Malaria - physiopathology</subject><subject>Plasmodium falciparum</subject><subject>Prophylaxis</subject><subject>Treatment Outcome</subject><issn>1860-6768</issn><issn>1860-7314</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1PwjAYhxujEUSvHs1ORg_Dfq3tjkDkIyFywZh4abq1w-lg2HYq_70jW9Abp76H5_ckfQC4RrCPIMQPSV76PoYwghAScQK6SDAYcoLoaXszzkQHXDj3DiGNCKTnoIOYiDlHuAvCwcbna1Uom6si0LZauSAM3krnA6_syngX3Flz_5W73Bt9Cc4yVThz1b498Dx-XI6m4XwxmY0G8zCljIswohQJoxlRKSIZJKmhiGClM5OSTCgec8Y41xmJMEsYxUgnJNKYmBQKrNOM9MBt493a8rMyzst17lJTFGpjyspJJjiKKRNHQQxxjUVRDfYbMLWlc9Zkcmvrf9udRFDuS8p9SXkoWQ9uWnOVrI3-w9t0NRA3wHdemN0RnRzOFsv_8rDZ5s6bn8NW2Q_JOOGRfHmaSD6evw4RRnJKfgGuhI0k</recordid><startdate>200603</startdate><enddate>200603</enddate><creator>Cunha-Rodrigues, Margarida</creator><creator>Prudêncio, Miguel</creator><creator>Mota, Maria M.</creator><creator>Haas, Werner</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200603</creationdate><title>Antimalarial drugs - host targets (re)visited</title><author>Cunha-Rodrigues, Margarida ; Prudêncio, Miguel ; Mota, Maria M. ; Haas, Werner</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4678-54418ed63ac13f03ce4132adfec3f8a7976677df3526b6421db35d23ec082dcf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antimalarials - therapeutic use</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Delivery Systems - trends</topic><topic>Drug Design</topic><topic>Drug Resistance</topic><topic>HGF/MET</topic><topic>Humans</topic><topic>Malaria</topic><topic>Malaria - drug therapy</topic><topic>Malaria - physiopathology</topic><topic>Plasmodium falciparum</topic><topic>Prophylaxis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cunha-Rodrigues, Margarida</creatorcontrib><creatorcontrib>Prudêncio, Miguel</creatorcontrib><creatorcontrib>Mota, Maria M.</creatorcontrib><creatorcontrib>Haas, Werner</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biotechnology journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cunha-Rodrigues, Margarida</au><au>Prudêncio, Miguel</au><au>Mota, Maria M.</au><au>Haas, Werner</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antimalarial drugs - host targets (re)visited</atitle><jtitle>Biotechnology journal</jtitle><addtitle>Biotechnology Journal</addtitle><date>2006-03</date><risdate>2006</risdate><volume>1</volume><issue>3</issue><spage>321</spage><epage>332</epage><pages>321-332</pages><issn>1860-6768</issn><eissn>1860-7314</eissn><abstract>Every year, forty percent of the world population is at risk of contracting malaria. Hopes for the erradication of this disease during the 20th century were dashed by the ability of Plasmodium falciparum, its most deadly causative agent, to develop resistance to available drugs. Efforts to produce an effective vaccine have so far been unsuccessful, enhancing the need to develop novel antimalarial drugs. In this review, we summarize our knowledge concerning existing antimalarials, mechanisms of drug‐resistance development, the use of drug combination strategies and the quest for novel anti‐plasmodial compounds. We emphasize the potential role of host genes and molecules as novel targets for newly developed drugs. Recent results from our laboratory have shown Hepatocyte Growth Factor/MET signaling to be essential for the establishment of infection in hepatocytes. We discuss the potential use of this pathway in the prophylaxis of malaria infection.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>16897712</pmid><doi>10.1002/biot.200500038</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1860-6768 |
| ispartof | Biotechnology journal, 2006-03, Vol.1 (3), p.321-332 |
| issn | 1860-6768 1860-7314 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68719468 |
| source | Wiley-Blackwell Journals; MEDLINE |
| subjects | Animals Antimalarials - therapeutic use Drug Delivery Systems - methods Drug Delivery Systems - trends Drug Design Drug Resistance HGF/MET Humans Malaria Malaria - drug therapy Malaria - physiopathology Plasmodium falciparum Prophylaxis Treatment Outcome |
| title | Antimalarial drugs - host targets (re)visited |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T16%3A58%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antimalarial%20drugs%20-%20host%20targets%20(re)visited&rft.jtitle=Biotechnology%20journal&rft.au=Cunha-Rodrigues,%20Margarida&rft.date=2006-03&rft.volume=1&rft.issue=3&rft.spage=321&rft.epage=332&rft.pages=321-332&rft.issn=1860-6768&rft.eissn=1860-7314&rft_id=info:doi/10.1002/biot.200500038&rft_dat=%3Cproquest_cross%3E20246855%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20246855&rft_id=info:pmid/16897712&rfr_iscdi=true |